Sinopia Biosciences

Sinopia Biosciences is a biotechnology company focused on advancing novel therapeutics using its proprietary computational drug discovery platform. The company's LEarn And DiScover (LEADS) platform combines high-throughput multi-omics data, artificial intelligence/machine learning, and network biology to identify and prioritize new drug targets and compounds. Sinopia's approach aims to transform drug discovery by leveraging advances in biology and technology, moving away from traditional target-based methods toward a data-driven approach.

The LEADS platform operates in two steps: Learn, which uses machine learning and network analysis of multi-omics data to identify disease mechanisms, and DiScover, which employs high-throughput screening to rapidly test millions of candidate molecules. This integrated approach allows Sinopia to analyze large-scale metabolomics datasets and explore applications in various therapeutic areas, including neurology, oncology, and immunology.

Sinopia's lead clinical candidate, SB-0110, was developed for Parkinson's disease using the LEADS platform. In preclinical studies with rodent and non-human primate models, SB-0110 showed potential to treat both Parkinson's symptoms and levodopa-induced dyskinesia, a common complication of current treatments. The compound also demonstrated possible cognitive-enhancing effects in primate models of Parkinson's disease. The company was preparing to begin IND-enabling studies for SB-0110.

In addition to its Parkinson's disease program, Sinopia is developing treatments for oral mucositis, a painful side effect of cancer therapies. The company received a USD 2.2 million Phase II SBIR grant from the National Institute of Dental and Craniofacial Research to advance its oral mucositis program to lead discovery and optimization.